Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
The Supreme Court ruled that when a trial judge resolves a factual dispute while interpreting a patent's wording — like what a scientific term meant to experts at the time — appeals courts must accept that specific factual finding unless it is clearly wrong, rather than reviewing it from scratch.
The decision reins in the Federal Circuit's longstanding practice of reviewing every part of a trial judge's patent-claim rulings from scratch, requiring deference to the judge's underlying factual findings while still allowing fresh review of the ultimate legal conclusion about what the patent means.
How it got here: A federal trial court upheld Teva's patent as valid; the Federal Circuit reversed after reviewing the trial court's findings from scratch; Teva asked the Supreme Court to review the standard used.
The Case in Depth
What happened
Teva Pharmaceuticals owns a patent covering a manufacturing method for Copaxone, a multiple sclerosis drug, describing its active ingredient's "molecular weight" as 5 to 9 kilodaltons. When Sandoz tried to market a generic version, Teva sued for infringement, and Sandoz argued the patent was invalid because "molecular weight" could be calculated three different ways and the patent never said which one applied.
The question before the Court
When judges have to resolve a factual dispute about what a technical term in a patent means, should appeals courts start over from scratch or defer to the trial judge unless clearly wrong?
The Court's answer
The Court ruled that appeals courts must defer to a trial judge's specific factual findings — like how scientists in the relevant field would understand a technical term — unless those findings are clearly wrong. This is the same deferential "clear error" standard trial-court fact-finding receives in every other kind of case, and the Court found no persuasive reason patent cases should be treated differently.
At the same time, the ultimate legal question of what a patent claim means remains open to fresh review on appeal. So the Federal Circuit can still freely re-examine how a trial judge interpreted the words of a patent, but it cannot brush aside the judge's underlying factual findings without showing they were clearly mistaken.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Patent owners and challengers litigating drug, technology, and other patents will now see more weight given to a trial judge's findings on technical facts, which could make some appeals harder to win by simply re-arguing expert testimony. Companies like Teva and Sandoz fighting over generic versions of brand-name drugs face different odds on appeal as a result.
What changes now
The case goes back to the Federal Circuit, which must now review the district court's factual finding about how a skilled scientist would read the chromatogram data only for clear error, not from scratch. Teva also identified two more instances where it says the Federal Circuit improperly applied de novo review; the Federal Circuit will consider those on remand. Whether Teva's patent is ultimately valid remains open pending that further review.
What this does not decide
The Court did not decide whether Teva's patent is actually valid or how "molecular weight" should ultimately be defined — it only decided what standard of review applies to factual findings underlying claim construction. It left for the Federal Circuit, on remand, two other disputed instances where Teva says the wrong standard was applied.
Concurrences and dissents
Dissent — Justice Thomas
“Because it does not, Rule 52(a)(6) does not apply, and the Court of Appeals properly applied a de novo standard of review.”The dissent's central objection that claim construction involves no genuine 'findings of fact.'
Justice Thomas agreed there is no special exception to Rule 52(a)(6) for patent claim construction, but argued the real question is whether claim construction actually involves 'findings of fact' at all. He concluded the subsidiary determinations judges make while construing patent claims are legal conclusions akin to statutory interpretation, not factual findings, because patents are government-granted rights binding the public rather than private agreements like contracts or deeds. He would have upheld the Federal Circuit's de novo review of the entire claim construction, including the disputed molecular-weight finding.
How the Court got there
The legal reasoning, step by step
- Federal Rule of Civil Procedure 52(a)(6) sets a 'clear command' that appeals courts must accept a trial judge's factual findings unless they are clearly erroneous, and the rule makes no exception for particular categories of facts, including those found while interpreting a patent claim.
- The Court explained that its earlier decision in Markman v. Westview Instruments, which assigned the job of interpreting patent claims to judges rather than juries, never created an exception to this ordinary rule for factual disputes along the way — it only decided who decides the ultimate legal question, not how factual sub-disputes get reviewed.
- Interpreting written documents like deeds or contracts is usually a pure legal question, but when a document uses technical terms whose meaning is disputed, courts may need outside evidence to determine what those terms meant to people in the relevant field at the time — and resolving disputes over that outside evidence is fact-finding subject to deferential review.
- The Court reasoned that trial judges, who sit through the entire evidentiary proceeding and can question expert witnesses directly, are better positioned than appeals judges reading a transcript to resolve these technical factual disputes, which further supports deferential review.
- Applying this framework, the Court held that when a district court relies only on the patent's own text and history, its claim construction is purely legal and reviewed fresh on appeal; but when it resolves a factual dispute using outside evidence, that specific finding gets deferential 'clear error' review, while the judge's final interpretation of the claim remains open to fresh review.
Doctrinal impact
Cases affected by this decision
Reaffirms Markman v. Westview Instruments, Inc. (517 U. S. 370)
The Court leaned on Markman's rule that judges, not juries, construe patent claims, while clarifying it created no exception to normal fact-review rules.
Reaffirms Pullman-Standard v. Swint (456 U. S. 273)
The Court relied on this case's rule that Rule 52(a) applies to both subsidiary and ultimate facts with no exceptions.